Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma

Our recent study demonstrated that a novel proteasome inhibitor NPI-0052 triggers apoptosis in multiple myeloma (MM) cells, and importantly, that is distinct from bortezomib (Velcade) in its chemical structure, effects on proteasome activities, and mechanisms of action. Here, we demonstrate that com...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Chauhan, Dharminder, Singh, Ajita, Brahmandam, Mohan, Podar, Klaus, Hideshima, Teru, Richardson, Paul, Munshi, Nikhil, Palladino, Michael A., Anderson, Kenneth C.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2008
Assuntos:
Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2214767/
https://ncbi.nlm.nih.gov/pubmed/18006697
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2007-08-105601
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados